SCHEMBL14320404

SCHEMBL14320404

COC(=O)c1cccc(-c2nc(Nc3ccc4c(c3)NC(=O)CS4)c3[nH]ncc3n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PDE5A O76074 2/20 0.45
ABCG2 Q9UNQ0 3/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
ROCK2 O75116 3/20 0.41
ABCB1 P08183 1/20 0.41
HPGD P15428 1/20 0.39
SYK P43405 4/20 0.39
JAK2 O60674 2/20 0.39
ABCC1 P33527 1/20 0.39
PIK3CA P42336 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135643 0.92 HTT (0.47) LMNAALDH1A1PDE5AABCG2ROCK2
SCHEMBL14320820 0.86 CRBN (0.48) LMNAPDE5AABCG2KDM4EMAPT
SCHEMBL14320889 0.85 SYK (0.46) ALDH1A1PDE5AABCG2KDM4EMAPT
SCHEMBL14320504 0.85 PDE5A (0.44) LMNAPDE5AABCG2KDM4EMAPT
SCHEMBL15650370 0.83 SYK (0.46) LMNAALDH1A1ROCK2SYKHTT
SCHEMBL14320556 0.82 JAK2 (0.44) LMNAALDH1A1ROCK2HPGDSYK
SCHEMBL17135645 0.82 HTT (0.40) LMNAALDH1A1KDM4EMAPTROCK2
SCHEMBL15651330 0.80 PDE5A (0.48) LMNAALDH1A1PDE5AABCG2KDM4E
SCHEMBL14320685 0.80 ABCG2 (0.40) LMNAALDH1A1PDE5AABCG2KDM4E
SCHEMBL14321208 0.80 PDE5A (0.52) LMNAPDE5AABCG2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK LMNA 3015/4885ALDH1A1 4333/4885PDE5A 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.